GERON ENROLLS FIRST PATIENT IN DRUG STUDY FOR ESSENTIAL THROMBOCYTHEMIA

  • MPNRF | May 3, 2021

    January 2011

    Geron Corporation has enrolled their first person in a Phase 2 clinical trial to test their drug (GRN163L) in patients with essential thrombocythemia. These drugs are aiming to target the leukemic stem cell, which Geron believes will “impact the biology of the disease”. This Phase 2 trial is testing the safety and efficacy of the drug.

    Click here to read the full article